Cytogen Quadramet Promotions Cited In FDA Ad Division Warning Letter
This article was originally published in The Pink Sheet Daily
A radio ad, website and patient video for the cancer pain therapy overpromise benefits and minimize risk to “a very sick and vulnerable population,” FDA says. The warning letter follows a 2001 “untitled” letter for Quadramet that also objected to unsubstantiated efficacy claims.
You may also be interested in...
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said
Pfizer will continue to support the insomnia product for up to six months.